New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...

Cliacil 1.200.000 IU film tablet - Kisa ürün bi̇lgi̇si̇ ...

Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...

Veuillez compléter ce formulaire pour communiquer avec Sanofi Canada. Tous les renseignements que vous fournissez seront conservés en conformité avec notre politique de confidentialité. Nous ...

이전에 2차 이상의 전신 요법에 실패한 만성 이식편대숙주 질환이 있는 성인 및 12세 이상의 소아 환자의 치료 ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...

Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

Les résultats du troisième trimestre 2024 seront commentés par le management au cours d'un webcast audio en direct avec la communauté financière. La présentation sera suivie d'une session de questions ...

Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois CP : Le tolebrutinib a permis d’allonger ...